BNP Paribas Financial Markets’s Viracta Therapeutics, Inc. Common Stock VIRX Stock Holding History

BNP Paribas Financial Markets’s Portfolio VIRX Stock Details VIRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2015 Q2	–	Sell	-6	Closed	-$2.86K	–	3637
2015 Q1	$2.86K	Buy	+6	New	+$3.03K	﹤0.01%	3398
2014 Q4	–	Sell	-17	Closed	-$26K	–	3316
2014 Q3	$26K	Buy	17 +13	+325%	+$18.8K	﹤0.01%	2982
2014 Q2	$5.1K	Buy	4 +1	+33%	+$1.16K	﹤0.01%	2573
2014 Q1	$3.58K	Sell	3 -2	-40%	-$2.33K	﹤0.01%	2501
2013 Q4	$4.87K	Buy	+5	New	+$5.17K	﹤0.01%	3110
2013 Q3	–	Sell	-58	Closed	-$63.7K	–	2740
2013 Q2	$63.7K	Buy	+58	New	+$64.6K	﹤0.01%	2626

Other funds holding VIRX

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

NMC

NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return

VAM

Visium Asset Management New York $1.43B AUM 3.58% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

GPP

Great Point Partners Greenwich, Connecticut $435M AUM 318.81% 1-Year Est. Return

FCM

Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Balyasny Asset Management Chicago, Illinois $77.1B AUM 42.89% 1-Year Est. Return

BNP Paribas Financial Markets's VIRX Position: Q2 2015 in Review

BNP Paribas Financial Markets sold out of Viracta Therapeutics, Inc. Common Stock (VIRX) in Q2 2015, closing a stake of 6 shares — an estimated $2.86K sold.

BNP Paribas Financial Markets first reported a position in VIRX in Q2 2013 and held it in 6 quarters. The position peaked at $63.7K in Q2 2013. 80 funds tracked by Wall St. Rank hold VIRX as of Q2 2015.

BNP Paribas Financial Markets reported no remaining Viracta Therapeutics, Inc. Common Stock position as of Q2 2015 after selling out during the quarter.
BNP Paribas Financial Markets sold 6 Viracta Therapeutics, Inc. Common Stock shares in Q2 2015, an estimated $2.86K.
BNP Paribas Financial Markets first reported a position in Viracta Therapeutics, Inc. Common Stock in Q2 2013 and held it in 6 quarters.
BNP Paribas Financial Markets's Viracta Therapeutics, Inc. Common Stock position peaked at $63.7K in Q2 2013.
80 funds tracked by Wall St. Rank held Viracta Therapeutics, Inc. Common Stock as of Q2 2015.

Based on BNP Paribas Financial Markets's 13F filing for Q2 2015, filed 14 Aug 2015.